Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.45 |
| ▸ | FYN | P06241 | 7/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19554533 | 0.86 | KDM4E (0.43) | FYNABCG2THRBALDH1A1HPGD | |
| SCHEMBL19555156 | 0.85 | CSNK1D (0.52) | FYNCSNK1DALDH1A1HPGDHSD17B10 | |
| SCHEMBL19554484 | 0.84 | FYN (0.48) | FYNALDH1A1HPGDHSD17B10NPC1 | |
| SCHEMBL19554601 | 0.83 | KDM4E (0.47) | KMOFYNALDH1A1HPGDHSD17B10 | |
| SCHEMBL19555182 | 0.81 | ALOX5AP (0.40) | FYN | |
| SCHEMBL19554550 | 0.80 | CHRM4 (0.41) | FYNABCB1ABCG2HPGDSALDH1A1 | |
| SCHEMBL19578187 | 0.80 | RXFP1 (0.41) | FYNABCB1ABCG2ALDH1A1HPGD | |
| SCHEMBL19554523 | 0.79 | KMO (0.45) | KMOFYNABCB1ABCG2HPGDS | |
| SCHEMBL19554968 | 0.78 | ULK1 (0.43) | FYNABCB1ABCG2HPGDSALDH1A1 | |
| SCHEMBL19555178 | 0.78 | KMO (0.44) | KMOFYNABCB1ABCG2HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11878979-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2024-01-23 | — | — | US | disclosed |
| CN-109311902-B | Substituted imidazo [1,2-b ] pyridazines, imidazo [1,5-b ] pyridazines, related compounds, and uses thereof | BIAL研发投资股份有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20220185814-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2022-06-16 | — | — | US | disclosed |
| US-11168087-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | Bial—R&D Investments, S.A. (PT) | 2021-11-09 | — | — | US | disclosed |
| EP-3452481-A1 | SUBSTITUTED IMIDAZO[1,2-b | Lysosomal Therapeutics Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| US-9868742-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b] pyridazines, related compounds, and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170355702-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b] PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-12-14 | — | — | US | disclosed |
| WO-2017192930-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355702-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b] PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, GALC | KMO 245/4885FYN 2136/4885ABCB1 1236/4885 |
| US-11168087-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | GBA1, GBA2, GALC | KMO 245/4885FYN 2136/4885ABCB1 1236/4885 |
| US-11878979-B2 | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders | GBA1, GBA2, GALC | KMO 245/4885FYN 2136/4885ABCB1 1236/4885 |
| US-20220185814-A1 | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GBA1, GBA2, GALC | KMO 245/4885FYN 2136/4885ABCB1 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.